Where can I find news about DNA?

The latest headlines, third-party analysis, and SEC filings for Ginkgo Bioworks Holdings, Inc. (DNA) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are DNA's SEC filings?

Ginkgo Bioworks Holdings, Inc. (DNA)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are DNA's earnings call transcripts?

Full earnings call transcripts for Ginkgo Bioworks Holdings, Inc. (DNA), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

DNA

Ginkgo Bioworks Holdings, Inc.

NYSE·Biotechnology · Healthcare

$9.99$0.28+2.88%

Market cap$672.73M·Market closed·Oct 23 4:00 PM EDT

News & Analysis

Hugging Face is launching a new AI model that lets scientists 'chat with DNA'
Hugging Face released a new AI model that allows users to "chat with DNA." Carbon-X can analyze and generate DNA and allows researchers to ask questions in plain language.
businessinsider.comOct 22, 2026 · 6:00 AM
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational targeted radiotherapeutic. The Ovarian Cancer Research Alliance sponsored the symposium, held October 16–18, 2026, in Philadelphia.
globenewswire.comOct 21, 2026 · 7:30 AM
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
zacks.comOct 20, 2026 · 7:15 PM
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
zacks.comOct 14, 2026 · 7:16 PM
What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation's X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.
benzinga.comOct 9, 2026 · 12:26 PM
Araceli Biosciences und Ginkgo Bioworks ermöglichen die zelluläre Bildgebung in großem Maßstab für das „Lab-in-the-Loop"-System von Nebula
/PRNewswire/ -- Araceli Biosciences und Ginkgo Bioworks (NYSE: DNA) gaben heute die Integration des Endeavor-High-Content-Imaging-Geräts von Araceli in
prnewswire.comOct 8, 2026 · 8:06 PM
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.
businesswire.comOct 8, 2026 · 4:10 PM
Araceli Biosciences y Ginkgo Bioworks incorporan la obtención de imágenes celulares al laboratorio de Nebula
/PRNewswire/ -- Araceli Biosciences y Ginkgo Bioworks (NYSE: DNA) han dado a conocer hoy la integración del instrumento de imágenes de alto contenido Endeavor
prnewswire.comOct 8, 2026 · 6:39 AM

SEC Filings

10-Q
Aug 6, 2026View on SEC
8-K
Aug 5, 2026View on SEC
8-K
Jul 30, 2026View on SEC
SC 13G/A
Jul 30, 2026View on SEC
8-K
Jun 12, 2026View on SEC
SC 13G/A
May 15, 2026View on SEC

Frequently Asked Questions About DNA

Where can I find news about DNA?: The latest headlines, third-party analysis, and SEC filings for Ginkgo Bioworks Holdings, Inc. (DNA) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are DNA's SEC filings?: Ginkgo Bioworks Holdings, Inc. (DNA)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are DNA's earnings call transcripts?: Full earnings call transcripts for Ginkgo Bioworks Holdings, Inc. (DNA), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

Ginkgo Bioworks Holdings, Inc.

Frequently Asked Questions About DNA

Ginkgo Bioworks Holdings, Inc.

Hugging Face is launching a new AI model that lets scientists 'chat with DNA'

Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™